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Introduction
In the mouse embryo, definitive hematopoiesis occurs in fetal liver, which consists of hepatoblasts expressing DLK-1 (Protein delta homolog 1), sinusoid endothelial cells expressing LYVE-1 (lymphatic vessel endothelial hyaluronic acid receptor 1) and hematopoietic cells expressing CD45 or Ter119 (Mouta Carreira et al., 2001; Tanimizu et al., 2003) . In fetal liver hematopoietic stem cells (HSCs) undergo extensive self-renewal and differentiate into mature hematopoietic cells, particularly erythrocytes (Johnson and Jones, 1973; Johnson and Moore, 1975; Dzierzak et al., 1998; Ema and Nakauchi, 2000; Sugiyama and Tsuji, 2006) . Both morphological observation and in vitro experiments suggest that fetal liver itself does not produce HSCs but is colonized by HSCs of extrinsic origin after 9.5 dpc (Johnson and Jones, 1973; Johnson and Moore, 1975; Houssaint, 1981; Cudennec et al., 1981) . Previously, we demonstrated that circulating HSCs expressing c-Kit could colonize fetal liver (Sugiyama et al., 2005) . Taken together, these data indicate that fetal liver provides instructive signals for HSC colonization, expansion and differentiation.
Integrin beta-1 is reportedly crucial for HSC colonization of fetal liver (Hynes and Yamada, 1982; Humphries et al., 1989; Hirsch et al., 1996; Frisch and Ruoslahti, 1997) . Interaction of integrin heterodimers with extra-cellular matrix factors (ECMs) likely functions as a homing mechanism and enable HSCs and hematopoietic progenitor cells to reside in fetal liver Tsai et al., 1987; Long and Dixit, 1990; Williams et al., 1991; Long et al., 1992; Klein et al., 1993; Strobel et al., 1997) . ECMs are produced in various cell 0925-4773/$ -see front matter Ó 2012 Elsevier Ireland Ltd. All rights reserved. http://dx.doi.org/10.1016/j.mod.2012.09.003 types and interact with cytokines to allow cells to interpret cytokine signaling in a particular context (Hynes and Yamada, 1982; Humphries et al., 1989; Frisch and Ruoslahti, 1997; Taipale and Keski-Oja, 1997 ).
In the current study, to determine which fetal liver component contributes to ECM production, we used flow cytometry to separate cells obtained from early fetal liver into hepatoblasts, sinusoid endothelial cells and hematopoietic cells, based on expression of surface molecules, and examined ECM expression in each component by real-time PCR, Western blot analysis and immunohistochemistry. Since Transforming Growth Factor (TGF)-betas are known to potentially regulate ECM production, we treated mouse embryos with their respective inhibitors and examined ECM gene expression in fetal liver (Nakamura et al., 1992; Ziyadeh et al., 1994; Chimal-Monroy and Diaz de Leon, 1999; Laping et al., 2002; Gaggioli et al., 2005) . Overall, we observe that hepatoblasts predominantly produce ECM factors under control of TGF-beta-1 in fetal liver.
2.
Materials and methods
Animals
ICR and C57BL/6J mice were purchased from Nihon SLC (Hamamatsu, Japan) and Kyudo (Tosu, Japan), respectively. Map2k4 +/À mice were provided by RIKEN BioResource Center (Tsukuba, Japan). Noon of the day of the plug was defined as 0.5 day post-coitum (dpc). Embryos at 10.25, 11.5, 12.5 and 14.5 dpc were dissected in PBS under a stereomicroscope. Animals were handled according to Guidelines for Laboratory Animals of Kyushu University. This study was approved by the Animal Care and Use Committee, Kyushu University (Approval ID: A21-068-0).
Flow cytometry
For hematopoietic cells, circulating blood and fetal liver cells at 11.5 and 12.5 dpc were filtered through a 40 lm nylon mesh and washed once with PBS. Cells were stained with FITC-conjugated anti-mouse CD71 (BD Biosciences, San Diego, CA) or Integrin beta-1 (CD29) (BD Biosciences), PE-conjugated anti-mouse Sca-1 (BD Biosciences), PE-Cy7-conjugated antimouse CD45 (eBioscience, San Diego, CA), APC-conjugated anti-mouse c-Kit (BD Biosciences) and APC-Cy7-conjugated anti-mouse Ter119 (eBioscience) Abs. Cell sorting was accomplished using a FACS Aria cell sorter (BD, Franklin Lakes, NJ). For hepatoblasts and sinusoid endothelial cells, 12.5 dpc fetal liver was digested in 1 mg/mL collagenase (Washington Biochem Co., Freehold, New Jersey) in alpha-MEM containing 10% FBS, filtered through 40-lm nylon mesh, and washed once with PBS. Cells were stained with FITC-conjugated anti-mouse DLK-1 Ab (MBL, Nagoya, Japan), PE-conjugated anti-mouse LYVE-1 Ab (MBL), PE-conjugated anti-mouse Hepatocyte growth factor (HGF) receptor Ab (eBioscience), Alexa Fluor 647-conjugated anti-mouse E-cadherin Ab (eBioscience), biotin-conjugated anti-mouse TGF-beta receptor type-2 (TGFR-2) Ab (R&D Systems, Minneapolis, MN), APC-conjugated anti-mouse CD31 Ab (Biolegend, San Diego, CA), PE-Cy7-conjugated anti-mouse CD45 Ab (eBioscience), PE-Cy7-conjugated anti-mouse Ter119 Ab (eBioscience), and APC-Cy7-conjugated streptavidin (eBioscience).
2.3.
Real-time PCR RNA was extracted from both sorted and unsorted fetal liver samples, and cultured cells using a RiboPure TM kit (Life Technologies, Carlsbad, CA), and mRNA was reverse transcribed using a high-capacity RNA-to-cDNA kit (Life Technologies). cDNA quality was evaluated by PCR amplification of mouse actin, beta (Actb). Thirty thermal cycles were used as follows: denaturation at 95°C for 10 s, annealing at 60°C for 20 s, and extension at 72°C for 20 s. Gene expression levels were measured by real-time PCR with TaqManÒ Gene Expression Master Mix and StepOnePlus TM real-time PCR (Life Technologies). All probes were from TaqManÒ Gene Expression Assays (Life Technologies). All samples were assayed in triplicate wells. mRNA levels were normalized to Actb and the relative quantity (RQ) of expression was compared with a reference sample.
Western blot analysis
For Western blot analysis, protein was extracted from sorted cells using QproteomeÒ Mammalian Protein Prep Kit (QIAGEN). Lysates of whole fetal liver, sinusoid endothelial cells, hepatoblasts and hematopoietic cells were run on 12.5% SDS-polyacrylamide gels (Ready Gels J, Bio-Rad Laboratories, Hercules, CA) concurrently with a pre-stained protein marker (Precision Plus Protein TM Standards, Bio-Rad Laboratories) using Laemmle buffer. Gels were trans-blotted onto a PVDF membrane (ImmobilonÒ-P Transfer Membrane, Millipore Billerica, MA). The membrane was blocked in 5% skim milk in TBS containing 0.1% Tween-20 (TBS-T) at 25°C for 1 h, washed with washing buffer (TBS-T) and reacted with 1:5000 mouse anti-TGF-beta-1 monoclonal Ab solution (R&D systems), 1:200 anti-Fibronectin Ab (Santa Cruz Biotechnology, Santa Cruz, CA), 1:2000 anti-Vitronectin Ab (EPITOMICS, Burlingame, CA) or 1:1500 rabbit anti-Beta-actin Ab (IMGE-NEX, Sorrento Valley, CA) at 25°C for 2 h. The membrane was then thoroughly washed and incubated in a solution of 1:1000 goat anti-mouse IgG-HRP conjugate (R&D systems) and 1:2500 goat anti-rabbit IgG-HRP conjugate (R&D systems) at 25°C for 1 h. After washing, signals were visualized by soaking the membrane in substrate solution (Amersham TM ECL Plus Western Blotting Detection System, GE Healthcare, Buckinghamshire, UK). Images were captured using ChemiDoc XRS (Bio-Rad Laboratories). Data were analyzed by Quantity One ver. 4.6.7 (Bio-Rad Laboratories) and displayed as intensity per mm 2 .
Immunohistochemistry
Injected or uninjected ICR mouse embryos were fixed in 2% paraformaldehyde in PBS overnight at 4°C and washed in PBS three times. After 27% sucrose infusion, embryos were embedded in OCT compound (Sakura Finetek, Tokyo, Japan) and frozen in liquid nitrogen vapor phase. Frozen embryos were sectioned at 20 lm, transferred onto glass slides (Matsunami, Osaka, Japan), and dried. After blocking in 1% BSA in PBS, sections were incubated with primary antibodies overnight at 4°C. After washing in PBS three times, sections were incubated with secondary antibodies and TOTO-3 (Life Technologies) for nuclear staining. Anti-mouse DLK-1 Ab (MBL), anti-Fibronectin Ab (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Vitronectin Ab (EPITOMICS, Burlingame, CA), antimouse CD31 Ab (BD Bioscience), anti-rat beta1-integrin Ab (BD Bioscience), anti-mouse Lyve-1 Ab (MBL), anti-mouse cKit Ab (R&D Systems), and anti-human SMAD family member 3 (SMAD3) phospho Ser423/Ser42 Ab (EPITOMICS) served as primary antibodies and donkey anti-rabbit IgG-Alexa555, donkey anti-goat IgG-Alexa488 and Alexa568, donkey antirat IgG-Alexa488 (all from Life Technologies), rabbit anti-hamster IgG-Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA) were used as secondary antibodies. Coverslips were mounted with fluorescence mounting medium (Dako Corporation, Carpinteria, CA). Slides were observed using an FV-1000 confocal microscope (Olympus, Tokyo, Japan).
2.6.
Intra-cardiac injection TGF-beta receptor type-1 Kinase Inhibitor (Merck, Darmstadt, Germany) and TGF-beta receptor type-1 Kinase Inhibitor II (Merck) were dissolved in DMSO at 5 mg/mL. 0.2-0.5 ll of inhibitors, anti-TGF-beta-1 blocking antibody (MAB240, R&D systems) or mouse IgG Isotype control (MBL) were administered to 10.25 dpc ICR mouse embryos by intra-cardiac injection, as previously described (Sugiyama et al., 2003 (Sugiyama et al., , 2005 Kulkeaw et al., 2009) . As stated by the manufacture, the optimal inhibitor concentration (Primary Target IC50) is 51 nM in TGFbeta receptor type-1 Kinase Inhibitor, and 23 nM in TGF-beta receptor type-1 Kinase Inhibitor II, respectively. Embryos were isolated under a stereomicroscope (Leica Microsystems MZ6, Wetzlar, Germany) in PBS. Both the uterus and deciduo capsularis were removed and the yolk sac was cut along yolk sac arteries with care to avoid excessive hemorrhage. The amnion was opened to allow needle access to the heart. The injection needle was produced by pulling a glass capillary (Narishige GC-10, Japan) using a micropipette puller (Narishige, Tokyo, Japan). Injected embryos were immediately subjected to a mouse whole embryo culture system within 1 h of isolation.
2.7.
Mouse whole embryo culture
Injected embryos were transferred to culture bottles containing 100% rat serum supplemented with 2 mg/ml glucose in a whole embryo culture system (Ikemoto Scientific Technology, Tokyo, Japan) and cultured for 6 or 12 h at 37°C with a continuous supply of the gas mixture (60% O 2 and 5% CO 2 balanced with N 2 ) in the dark (Osumi-Yamashita et al., 1997) . After whole embryo culture, embryos exhibiting no conspicuous bleeding or anomalies were analyzed for mRNA and protein expression. In addition, some fetal liver samples were isolated from embryos, pooled, filtered through a 40 lm nylon mesh, and their cell number counted.
In vitro culture
Hepatoblasts expressing DLK-1 were sorted from fetal liver at 12.5 dpc by flow cytometry, and 10,000 were cultured in 96-well plates with Opti-MEM (Life Technologies) containing 2% of fetal bovine serum in the presence or absence of TGFbeta-1 (10 ng/mL) (Wako, Osaka, Japan). After 6 h of culture, cells were collected and analyzed for mRNA expression.
Results

Integrin expression on fetal liver hematopoietic cells
Previously, it was reported that chimeric embryos generated with a component of integrin beta 1 (Itgb1)-deficient embryonic stem cells exhibited Itgb1 null hematopoietic cells in the YS and blood, but not in fetal liver, suggesting that Itgb1 is crucial for hematopoietic cell colonization of fetal liver (Hirsch et al., 1996) . To confirm expression of Integrin beta-1 protein on hematopoietic cells, we first performed flow cytometry on blood and fetal liver cells obtained from 11.5 dpc mouse embryos. Integrin beta-1 was expressed on 94.9% of HSCs (CD45+/c-Kit+/Sca-1+) and 86.4% of erythroid cells (CD45À/Ter119+) in fetal liver, and on 96.8% of HSCs (CD45+/c-Kit+/Sca-1+) in circulation, whereas it was expressed on only 0.85% of circulating erythroid cells (CD45À/Ter119+) (Fig. 1A) . Immunohistochemistry of fetal liver sections at 11.5 and 12.5 dpc showed that hematopoietic cells inside blood vessels surrounded by CD31-expressing endothelial cells did not express Integrin beta-1, while most hematopoietic cells outside blood vessels did, in agreement with flow cytometry data (Fig. 1B) . To identify the alpha-chain partner of the beta-1-containing heterodimer, integrin-alpha expression was examined at stages ranging from HSCs to mature erythroid cells in mouse fetal liver using real-time PCR. As shown in Fig. S1 , HSCs and various stages of differentiated erythroid cells were isolated by flow cytometry from fetal liver at 12.5 dpc based on expression of the cell surface markers Sca-1, c-Kit, CD71 and Ter119 (see Fig. S1 for a definition of lineage markers) (Suzuki et al., 2003; Inoue et al., 2011) . When integrin-alpha expression was compared during erythropoiesis, integrin alpha V (ItgaV), Itga5, Itga6, and Itga9 mRNAs were predominantly expressed in HSC and hematopoietic progenitor cell fractions ( Fig. 2A) . No integrin-alpha expression was detected in the mature erythroid cell fraction (Sca-1À/c-KitÀ/CD71À/Ter119+). When integrin-alpha expression was evaluated in each hematopoietic cell fraction, Itga4 and Itga6 were highly expressed in both HSC and BFU-E fractions, and Itga4 was also expressed in relatively mature erythroid cells (Fig. 2B) . Taken together, these observations imply that integrins expressed on both HSCs and hematopoietic progenitor cells interact with ECM binding partners, enabling cells to adhere properly to fetal liver.
ECM factor expression in fetal liver
To investigate the production of ECMs, we examined expression of several ECM genes in fetal liver at 12.5 and 14.5 dpc using real-time PCR. Vitronectin (Vtn) and fibronectin1 (Fn1) mRNAs were predominantly expressed in fetal liver (Fig. 3A) . Morphological observation of fetal liver sections at 14.5 dpc revealed that hepatoblasts expressing DLK-1 were in close contact with HSCs and hematopoietic progenitor cells expressing c-Kit, implying that hepatoblasts may supply factors governing activities of HSCs and hematopoietic progeni- Supplementary Fig. S1 . Itga4 was expressed in fractions (3) and (4), which represent relatively mature erythroid cells.
tor cells (Fig. 3B ). As shown in Fig. 3C , fractions of hepatoblasts, sinusoid endothelial cells and hematopoietic cells were isolated from mouse fetal liver at 12.5 dpc by flow cytometry based on the following markers: hepatoblasts, CD45À/Ter119À/DLK-1+; sinusoid endothelial cells, CD45À/ Ter119À/LYVE-1+/CD31+; and hematopoietic cells, CD45+/ Ter119+. We observed that 96.5% of hepatoblasts also expressed the hepatoblast marker E-cadherin. To investigate A B C D Fig. 3 -Separation of fetal liver components and expression of ECM factors. (A) Expression of laminin, alpha 1 (Lama1), laminin B 1 (Lamb1), laminin, beta 2 (Lamb2), laminin, beta 3 (Lamb3), laminin, gamma 1 (Lamc1), fibronectin 1 (Fn1), vitronectin (Vtn) and tenascin C (Tnc) was examined in fetal liver samples at 12.5 and 14.5 dpc by real-time PCR. Expression of Vtn and Fn1 was predominantly seen in fetal liver. (B) Sections were prepared from ICR mouse embryos at 14.5 dpc, stained with antibodies to c-Kit and DLK-1, as well as TOTO-3 to define nuclei, and observed by confocal microscopy. Hepatoblasts expressing DLK-1 were in close contact with HSCs and hematopoietic progenitor cells expressing c-Kit. Original magnification was 40·. (C) A single cell fetal liver suspension was obtained at 12.5 dpc, and expression of CD45/Ter119, DLK-1, E-cadherin, HGF receptor, LYVE-1, CD31 and TGFR2 was analyzed by flow cytometry. (1) which fetal liver component contributes to ECM-production, expression of genes encoding ECM factors was examined in hepatoblasts, sinusoid endothelial cells and hematopoietic cells by real-time PCR. All ECM genes analyzed, including laminin B 1(Lamb1), laminin, beta2(Lamb2), Vtn, Fn1 and tenascin C (Tnc), were highly expressed in hepatoblasts compared to sinusoid endothelial cells and hematopoietic cells (Fig. 3D) . Both Fibronectin and Vitronectin were detected in fetal liver at 12.5 dpc by immunohistochemistry (Fig. 3E ). In addition, Western blot analysis showed that hepatoblasts expressed Vitronectin and Fibronectin proteins at levels higher than those seen in sinusoid endothelial cells and hematopoietic cells (Fig. 3F) . To characterize hepatoblast function in fetal liver, we analyzed Map2k4 (mitogen-activated protein kinase kinase 4, formerly known as Sek1 and MKK4) À/À mouse embryos, which lack fetal liver hepatoblasts (Nishina et al., 1997a (Nishina et al., , 1997b (Nishina et al., , 1999 Watanabe et al., 2002) . Immunohistochemistry indicated that expression of Fibronectin and Vitronectin proteins was lower relative to that seen in wild-type mouse embryos in fetal liver of Map2k4 À/À mouse embryos (Fig. 3G ). Both mRNA and protein expression data and analysis of mutant embryos suggest that hepatoblasts expressing DLK-1 are primarily responsible for ECM production in fetal liver.
Regulation of ECM production by TGF-beta-1
We next asked how ECM production in hepatoblasts is regulated. Based on findings suggesting that TGF-betas and HGF regulate ECM production (Nakamura et al., 1992; Ziyadeh et al., 1994; Chimal-Monroy and Diaz de Leon, 1999; Laping et al., 2002; Gaggioli et al., 2005) , we analyzed gene expression of Tgfb1, Tgfb2, Tgfb3 and Hgf in whole fetal liver samples at 12.5 and 14.5 dpc (Fig. 4A) . Tgfb1 was predominantly expressed in fetal liver at both stages. TGF-beta-1 protein was also detected by Western blot analysis in fetal liver at 12.5 dpc (Fig. 4B) . To investigate whether TGF-beta-1 and HGF signals regulate ECM production in fetal liver, we used real-time PCR to examine expression of Tgfb1 and Tgfbr2, which encodes the TGF-beta receptor type 2 (TGFR-2), and Hgf and Met, which encodes HGF receptor, in hepatoblasts, sinusoid endothelial cells and hematopoietic cells. Tgfb1 was predominantly expressed in sinusoid endothelial cells and hematopoietic cells, whereas Tgfbr2 was predominantly expressed in both sinusoid endothelial cells and hepatoblasts (Fig. 4C) . Western blot analysis showed that TGF-beta-1 protein was highly expressed in both hepatoblasts and sinusoid endothelial cells (Fig. 4D ). Tgfb1 and Tgfbr2 expression was detected in HSCs and at each stage of differentiated erythroid cells isolated from fetal liver at 12.5 dpc (Fig. S2) . By contrast, both Hgf and Met were predominantly expressed in hepatoblasts. Flow cytometric analysis also showed that TGFR-2 and HGF receptor proteins were expressed in 56.2% and 68.5% of hepatoblasts, respectively (Fig. 3C) .
To further investigate which signal functions in ECM production, TGFR2 inhibitors were administered to mouse embryos using an intra-cardiac injection technique that we developed for use in 10.0-10.5 dpc embryos (Sugiyama et al., 2003 (Sugiyama et al., , 2005 Sasaki et al., 2010) . After hepatoblasts develop in fetal liver, circulating hematopoietic cells home to fetal liver after 9.5 dpc (Johnson and Jones, 1973; Johnson and Moore, 1975; Houssaint, 1981; Cudennec et al., 1981; Sugiyama et al., 2005) . To rule out effects of ECM gene expression by hematopoetic cells (Fig. 3D) , we chose to inject inhibitors at 10.25 dpc, when fetal liver is predominantly comprised of hepatoblasts. Following injection, we maintained embryos for variable time periods in a whole embryo culture system (Osumi-Yamashita et al., 1997; Kulkeaw et al., 2009) . Twelve hours after injection of a specific, cell-permeable TGF-beta receptor type-1 Kinase Inhibitor, Vtn, Fn1 and Tnc expression levels were down-regulated relative to controls (Fig. 5A) . Injection of a different TGF-beta receptor type-1 Kinase Inhibitor II promoted a detectable decrease in Vtn expression by 6 h of culture and significant decreases in Vtn, Fn1 and Tnc expression levels relative to controls after 12 h of culture (Fig. 5B) . TGF-beta receptor type-1, also known as ALK5, binds to both growth differentiation factor-1 (GDF1) and TGF-betas. To determine whether down-regulation of ECM genes resulted from specific alterations in TGF-beta-1 signaling, anti-TGF-beta-1 blocking antibody was injected into mouse embryos. As shown in Fig. 5C , Vtn, Fn1 and Tnc expression was down-regulated after 12 h of whole embryo culture. To confirm that TGF-beta-1 signaling is down-regulated after administration of anti-TGF-beta-1 blocking antibody, injected embryos were stained with anti-phosphorylated SMAD3 antibody. A 19.4% decrease in SMAD-phosphorylation was observed after injection of E F G Fig. 3 -continued anti-TGF-beta-1 blocking antibody (Fig. S3 ). As shown in Fig. S4 , some DLK-1 positive and negative cells were stained with anti-phosphorylated SMAD3 Ab in fetal liver at 10.5 dpc. Taken together, it is likely that TGF-beta-1 signaling in both hepatoblasts expressing DLK-1 and non-hepatoblasts was down-regulated after administration of anti-TGF-beta-1 blocking antibody.
To further investigate how TGF-beta-1 controls ECM production in hepatoblasts, we sorted hepatoblasts expressing DLK-1 and cultured them in the presence of TGF-beta-1. After 6 h of culture, Vtn, Fn1 and Tnc expression was up-regulated (Fig. 5D) . Taken together, these data strongly suggest that TGF-beta-1/TGFR-2 signaling promotes ECM production by hepatoblasts in fetal liver.
Discussion
Hepatoblasts were originally regarded as common progenitors of hepatocytes and biliary epithelial cells and thought to support liver construction through formation of a mesh-like structure (Tanimizu et al., 2003; Sasaki and Sonoda, 2000) . Recently, it was reported that expression of SCF and EPO by A TGF-beta receptor type-1 Kinase Inhibitor (inhibitor 1) was administered to ICR mouse embryos at 10.25 dpc by intra-cardiac injection, and embryos were then cultured in a whole embryo culture system. Left and right bars show control (DMSO injection) and sample (inhibitor injection) responses, respectively. Expression of Vtn, Fn1 and Tnc genes was slightly down-regulated after 6 h and then more significantly so at 12 h of whole embryo culture compared to controls. (B) TGF-beta receptor type-1 Kinase Inhibitor II (inhibitor 2) was administered as in (A). Expression of Vtn, Fn1 and Tnc was slightly and then significantly downregulated relative to controls after 6 and 12 h of whole embryo culture, respectively. (C) Anti-TGF-beta-1 blocking antibody was administered as in (A). Left and right bars show control (Isotype IgG injection) and sample (blocking antibody injection), respectively. Expression of Vtn, Fn1 and Tnc was down-regulated after 12 h of whole embryo culture. (D) Hepatoblasts expressing DLK-1 were sorted from 12.5 dpc fetal liver by flow cytometry and 10,000 cells were cultured with or without TGFbeta-1 (10 ng/mL). Vtn, Fn1 and Tnc expression was up-regulated after 6 h of in vitro culture with TGF-beta-1.
hepatoblasts promotes HSC expansion and differentiation (Lodish et al., 2010; Sugiyama et al., 2011) . ECMs act together with cytokines to maximize cytokine signaling in specific tissues (Hynes and Yamada, 1982; Humphries et al., 1989; Frisch and Ruoslahti, 1997; Taipale and Keski-Oja, 1997) . Based on integrin expression patterns, we hypothesized that their binding partners were ECM proteins. Following comparison of integrin-alpha in each hematopoietic cell fraction, we found that Itga4 and Itga6 are highly expressed in HSC and BFU-E fractions. It is reported that Integrin alpha-4 accelerates erythroid cell differentiation but does not affect HSC colonization in fetal liver (Yanai et al., 1994; Arroyo et al., 1999) . Our data suggest that regulation of erythroid cell differentiation through Integrin alpha-4 occurs primarily at the level of HSCs and BFU-E in fetal liver. We found that Itga5, Itga9 and ItgaV were moderately expressed in HSC and BFU-E fractions. Since hematopoietic cells derived from Itga5, Itga9 or ItgaV single knockout mice can colonize fetal liver, it is likely that only Integrin beta-1 is specifically required for hematopoietic cell colonization of fetal liver and that various Integrin alpha can substitute for each other to some extent (Taverna et al., 1998; Bader et al., 1998; Huang et al., 2000) . In fetal liver, Vtn was highly expressed among several ECM genes at both 12.5 and 14.5 dpc, and Vitronectin protein was detected at high levels in hepatoblasts at 12.5 dpc. Vtn-deficient mouse embryos reportedly show no abnormalities (Zheng et al., 1995) , suggesting that other ECM factors compensate for its loss. On the other hand, fibronectin-deficient mice die early in embryogenesis probably due to abnormal mesoderm development (George et al., 1993) . Fibronectin binds to Integrins alpha-4/beta-1, alpha-5/beta-1 and alpha-V/beta-1. These results and our gene expression data suggest that Integrin alpha-4/beta-1 and Fibronectin signaling is likely important for HSC differentiation.
Among cells comprising the fetal liver, hepatoblasts predominantly produce ECM factors. Here, we evaluated mouse embryos lacking Map2k4 À/À , the gene encoding the dual specificity mitogen-activated protein kinase kinase 4 protein. These mice reportedly lack fetal liver hepatoblasts (Nishina et al., 1997a (Nishina et al., , 1997b (Nishina et al., , 1999 Watanabe et al., 2002) . Morphological examination indicated that Map2k4 À/À mutant embryos developed normally except for their liver, which exhibited an unusual pouch-like morphology and contained hematopoietic cells. The hematopoietic activity of these cells is reportedly normal (Nishina et al., 1999) . Although it is formally possible that MAPK signaling could directly impact ECM factor expression, our findings overall strongly suggest that down-regulation of Fibronectin and Vitronectin production is due to loss of hepatoblasts. We also show that TGF-beta-1/TGFR-2 signaling functions in ECM production by fetal liver cells, predominantly hepatoblasts. TGF-beta-1/TGFR-2 signaling regulates diverse processes such as cell growth, differentiation, and apoptosis in adult animals and in embryogenesis (Shi and Massague, 2003; Watabe et al., 2003; Moustakas and Heldin, 2009 ). We found that sinusoid endothelial cells, hematopoietic cells and hepatoblasts express TGF-beta-1 mRNA and protein.
Flow cytometry analysis showed that TGFR-2 was expressed in 1.8% of hematopoietic cells, 56.2% of hepatoblasts and 99% of sinusoid endothelial cells, suggesting that hepatoblasts and sinusoid endothelial cells are affected by TGF-beta-1/TGFR-2 signaling to a greater extent than hematopoietic cells. The observation that a high proportion of sinusoid endothelial cells expresses TGFR-2 is compatible with previous reports that TGF-beta-1/TGFR-2 signaling controls sinusoid endothelial cell differentiation in addition to normal angiogenesis (Shi and Massague, 2003; Watabe et al., 2003; Moustakas and Heldin, 2009; Yoshida et al., 2007) . Interestingly, half of all hepatoblasts expressed TGFR-2, suggesting a functional separation of hepatoblasts based on TGFR-2 expression. Although expression levels of Tgfb2 and Tgfb3 are lower than that of Tgfb1 in fetal liver at both 12.5 and 14.5 dpc (Fig. 4A) , we cannot exclude the possibility that these factors function in ECM production by hepatoblasts, since Tgfb1-deficient mouse embryos exhibit no gross embryonic abnormalities, suggesting a compensatory mechanism (Shull et al., 1992) .
Taken together with data showing that TGF-beta-1 up-regulates Vtn, Fn1 and Tnc expression in vitro, TGF-beta-1/TGFR-2 signaling likely regulates ECM-production in fetal liver hepatoblasts in vivo, facilitating interactions with Integrins. In embryos injected with either TGF-beta receptor type-1 Kinase Inhibitor or TGF-beta receptor type-1 Kinase Inhibitor II, the number of fetal liver cells was significantly decreased after 12 h of whole embryo culture (Fig. S5) . It is also possible that treatment with TGF-beta-1 inhibitors may alter cell proliferation. That possibility will be investigated in future studies.
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